Back to Search
Start Over
The feasibility of venetoclax and decitabine in therapy-related acute myeloid leukemia with concurrent advanced non-hematological malignancies.
- Source :
-
Leukemia Research . Sep2019, Vol. 84, pN.PAG-N.PAG. 1p. - Publication Year :
- 2019
-
Abstract
- Highlights from the article: We retrospectively reviewed all AML patients treated at City of Hope between June 2016 and April 2019, and identified 8 patients with t-AML and active advanced non-hematological malignancies who received VEN-HMA. All patients were treated with VEN-HMA for newly diagnosed AML except for one who was treated with the combination for r/r AML after failing 2 prior AML therapies. Five patients received concurrent treatment for the underlying non-hematological malignancies, including hormonal therapies, immunotherapy, tyrosine kinase inhibitor and chemotherapy (Table 1). 4 S. Kayser, K. Döhner, J. Krauter, The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML, Blood., 117, 2011, 2137-2145Kayser S, Döhner K, Krauter J, et al.
- Subjects :
- *KARYOTYPES
*ACUTE myeloid leukemia
*IMMUNOTHERAPY
Subjects
Details
- Language :
- English
- ISSN :
- 01452126
- Volume :
- 84
- Database :
- Academic Search Index
- Journal :
- Leukemia Research
- Publication Type :
- Academic Journal
- Accession number :
- 137947208
- Full Text :
- https://doi.org/10.1016/j.leukres.2019.106196